1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,624 | 0,659 | 13:17 | |
| 0,624 | 0,659 | 12:47 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Mira Pharmaceuticals, Inc.: MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review | 248 | GlobeNewswire (Europe) | MIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics... ► Artikel lesen | |
| MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 16.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.09. | Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? | 2 | Benzinga.com | ||
| 01.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08. | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 31.07. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 30.07. | MIRA Pharmaceuticals completes toxicology studies for two candidates | 2 | Investing.com | ||
| 30.07. | MIRA Pharmaceuticals: Toxikologische Studien für zwei Wirkstoffkandidaten abgeschlossen | 5 | Investing.com Deutsch | ||
| 10.07. | MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 | 1 | Investing.com | ||
| 10.07. | MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain | 441 | ACCESS Newswire | Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA... ► Artikel lesen | |
| 06.07. | MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction | 314 | ACCESS Newswire | New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential MIAMI, FL / ACCESS Newswire / July 6, 2026 / MIRA Pharmaceuticals... ► Artikel lesen | |
| 06.07. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 25.06. | Mira Pharmaceuticals reports preclinical data on pain drug candidate | 3 | Investing.com | ||
| 25.06. | MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC | 353 | ACCESS Newswire | Data show Mira-55 does not produce the central nervous system effects associated with THC and acts through a distinct pharmacological mechanism, while demonstrating anxiolytic activity, which THC does... ► Artikel lesen | |
| 25.06. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06. | MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN | 3 | Investing.com | ||
| 17.06. | MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy | 916 | ACCESS Newswire | Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center MIAMI, FL / ACCESS Newswire / June 17... ► Artikel lesen | |
| 17.06. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 08.06. | Mira Pharmaceuticals bestellt Andriy Mushak zum externen CFO | 2 | Investing.com Deutsch | ||
| 04.06. | MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 | 301 | ACCESS Newswire | Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances Strategic Flexibility for Future Licensing and Partnership Opportunities MIAMI, FL / ACCESS Newswire / June... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,80 | -0,41 % | Nicht Bayer oder BioNTech: Diese attraktiv bewertete Biotechnologie-Aktie ist jetzt ein klarer Kauf! | © Foto: Sangharsh Lohakare auf Unsplash.Die Aktie von US-Biotechnologiekonzern Regeneron bietet nach einer Korrektur in den vergangenen Wochen eine fundamental attraktive Einstiegsgelegenheit.
Biotechnologie... ► Artikel lesen | |
| EVOTEC | 2,890 | -1,63 % | AKTIEN IM FOKUS: Aktien aus Diagnostik- und Laborbranche gesucht | FRANKFURT (dpa-AFX) - Aktien aus dem Segment Wirkstoffforschung, Diagnostik und Laborausrüstung haben am Dienstag auf den Kauflisten von Anlegern gestanden. Den Dax führten die Papiere von Qiagen und... ► Artikel lesen | |
| BB BIOTECH | 52,90 | +1,15 % | BB Biotech: KI verändert das Wie, nicht das Was | BB Biotech verbindet seit mehr als 30 Jahren wissenschaftliche Expertise mit einem konsequenten Investmentansatz im Biotechnologiesektor. Mit künstlicher Intelligenz entwickelt das Unternehmen diesen... ► Artikel lesen | |
| QIAGEN | 40,635 | +0,23 % | QIAGEN N.V.: QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery | New IPA Investigator lets researchers ask biological questions in natural language and examine the scientific evidence behind the results New QIAGEN Discovery Platform extends AI into drug... ► Artikel lesen | |
| AMGEN | 359,90 | +0,63 % | Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 | ||
| NOVAVAX | 9,990 | -0,70 % | Novavax-Aktie +20%: Woher kommt plötzlich die Fantasie? | Die Novavax-Aktie schoss zum Wochenauftakt um +20% in die Höhe und ging am Montagabend fast auf einem neuen 2-Jahreshoch aus dem Handel. Was steckt hinter dem Kurssprung des Impfstoffherstellers und... ► Artikel lesen | |
| STRYKER | 249,20 | +0,77 % | Dividendenbekanntmachungen (30.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1763 EUR ADVANCED FLOWER CAPITAL INC US00109K1051 0,05 USD 0,044 EUR AGNC INVESTMENT... ► Artikel lesen | |
| BIOGEN | 199,82 | +0,96 % | Kampf um den 40-Milliarden-US-Dollar-Alzheimer-Markt: So positionieren sich Eli Lilly, Biogen, Roche, Otsuka und NeuroThera | ||
| ILLUMINA | 241,95 | -0,43 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,705 | -0,48 % | CRISPR Therapeutics AG: CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 | ||
| OCUGEN | 0,954 | +2,80 % | Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate | European Affiliate, based in Amsterdam, to support upcoming marketing authorization submissions, OCU410 Phase 3 development program, and potential commercialization in Europe MALVERN, Pa., Oct. 06... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,044 | +4,50 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 25,550 | +1,19 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity | Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735
Monthly and Every-Other-Week Subcutaneous Regimens to also... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | NSE - SANGAMO THERAPEUTICS, INC - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| INFLARX | 1,493 | +6,49 % | InflaRx N.V.: InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development | Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen |
Das Unternehmen MIRA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,16 % bei einem Aktienkurs von 0,626 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MIRA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.